Menu
Annual · values202520242023202220212020201920182017201620152014
Operating Cash Flow16.81 B USD8.82 B USD4.24 B USD7.08 B USD7.26 B USD6.50 B USD4.84 B USD5.52 B USD5.62 B USD4.85 B USD2.77 B USD4.37 B USD
Depreciation & Amortization2.00 B USD1.77 B USD1.53 B USD1.52 B USD1.55 B USD1.32 B USD1.23 B USD1.61 B USD1.57 B USD1.50 B USD1.43 B USD1.38 B USD
Stock-Based Compensation626.00 M USD645.60 M USD628.50 M USD371.10 M USD342.80 M USD308.10 M USD312.40 M USD279.50 M USD281.30 M USD255.30 M USD217.80 M USD156.00 M USD
Capital Expenditures-7.84 B USD-5.06 B USD-3.45 B USD-1.85 B USD-1.31 B USD-1.39 B USD
Cash Flow from Investing-10.97 B USD-9.30 B USD-7.15 B USD-3.26 B USD-2.76 B USD-2.26 B USD-8.08 B USD1.91 B USD-3.78 B USD-3.14 B USD26.80 M USD-3.91 B USD
Cash Flow from Financing-2.21 B USD1.23 B USD3.50 B USD-5.41 B USD-4.13 B USD-3.14 B USD-2.32 B USD-5.90 B USD142.60 M USD-559.80 M USD-2.92 B USD-75.10 M USD
Dividends Paid5.38 B USD4.68 B USD4.07 B USD3.54 B USD3.09 B USD2.69 B USD2.41 B USD2.31 B USD2.19 B USD2.16 B USD2.13 B USD2.10 B USD
Stock Buybacks4.11 B USD2.50 B USD750.00 M USD1.50 B USD1.25 B USD500.00 M USD4.40 B USD4.15 B USD299.80 M USD600.10 M USD749.50 M USD800.00 M USD
Free Cash Flow5.96 B USD414.30 M USD-3.15 B USD4.60 B USD5.39 B USD4.47 B USD

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. Headquartered in Indianapolis, Indiana, the company focuses on therapies addressing diabetes, oncology, immunology, neuroscience, and cardiometabolic conditions. Its portfolio includes medicines for chronic metabolic diseases, cancer treatments aimed at specific tumor types, and immunology drugs targeting inflammatory and autoimmune disorders. Eli Lilly and Company serves healthcare systems, hospitals, and pharmacies worldwide, with a strong presence in major markets such as the United States, Europe, China, and Japan. The company operates across the full pharmaceutical value chain, from research and clinical development to large-scale manufacturing and global distribution. Through its focus on innovative, science-driven therapies for complex diseases, Eli Lilly and Company plays a significant role in the healthcare sector, supporting physicians and patients with branded medicines that are integrated into standard treatment protocols across multiple therapeutic areas.